Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES. Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO
|
|
- June Stone
- 5 years ago
- Views:
Transcription
1 Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO 0
2 Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forwardlooking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Moberg Pharma s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Moberg Pharma s interim or annual reports, prospectuses or press releases. 1 1
3 Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Net Sales grew to 286 MSEK (full year 2015) - U.S. OTC Sales operations - Products sold in 40+ countries - 35 employees in Sthlm and NJ Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior PII data for MOB015 Market Cap ~750 MSEK (OMX:MOB) 2 2
4 Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Outlook Profitable growth, targeting a long-term EBITDA margin of at least 25% Strategic elements Growth strategy - Organic growth - M&A/Innovation engine Build value through combining Brand/IP Equity 3 3
5 2015 Continued growth and doubling of profit
6 Highlights from Q415 and Q116 to date Q415 net sales grew by 7% to MSEK 54 Year-on-year, 2015 net sales grew by 43% (21% at fixed exchange rates) and EBITDA improved by 83% Asian launch driving growth in distributor sales Innovation engine progress Bupi Ph II results, Colep, Cadila, reg meetings SEK 300 million raised in the Nordic bond market to finance growth and acquisitions Divestment of three non-core brands enable increased focus on strategic assets 5 5
7 Growth in 2015 improved EBITDA with 83% m m Net Sales, MSEK 286 (+43%) EBITDA, MSEK EBITDA Commercial Operations, MSEK % 16% 22% 24% 68 (+58%) 46 (+83%) NOTE: EBITDA Commercial Operations does not include R&D and Business Development expenses for future products outside existing brands 6
8 23 consecutive quarters of Sales growth Product Sales, TTM, MSEK Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q
9 P&L - Sales growth and doubling of profit P&L Summary (MSEK) Q Q FY 2015 FY 2014 Revenue Gross profit % 68% 72% 75% 75% SG & A R&D existing product portfolio 1) Other operating income/operating expenses EBITDA Commercial Operations % 16% 21% 24% 22% R&D & BD future products 2) EBITDA % 8% 8% 16% 13% Depreciation/amortization Operating profit (EBIT) ) Research and development expenses existing product portfolio includes R&D expenses for new product variants under existing brands, regulatory work and quality. 2) Research and development expenses - future products includes R&D expenses for new product candidates, for example MOB Due to the rounding component, totals may not tally. 8
10 Majority of revenue from direct OTC sales Launches in Asia drives RoW product sales Distribution of revenue, January December 2015 Sales via distributors 28% JointFlex 13% Kerasal 11% Other 21% RoW 15% Europe 11% Direct OTC Sales 72% Nalox/ Kerasal Nail 55% Americas 74% Channels Products Geography 9 9
11 Solid cash position and positive cash flow Full-year 2015 Full-year 2014 Operative cash flow +31 MSEK +16 MSEK Cash position 45 MSEK 62 MSEK Not including: Bond issue of 300 MSEK closed in January 2016 Bond structure also allows tap issues of additional 300 MSEK Divestment of three non-core brands for 10 MUSD closed in April
12 Progress in Commercial Operations
13 Focus on strategic brands Strategic brands Kerasal - Foot care Emtrix Balmex - Diaper rash Domeboro - Derma/Skin irritation Mature brands Divested April 1, 2016 Jointflex - External analgesic Vanquish - Internal analgesic Fergon - Iron supplement 12 12
14 Kerasal Nail - the OTC market leader in the U.S. No 1 with 22% market share in Q ) Key claim visible difference in 2 weeks. Product supported by 4 clinical studies Available at > points of sale 13 1) Retail sales of nail fungus products excluding private label in Multioutlet Stores over the last 52 weeks ending December 27, 2015 as reported by SymphonyIRI 13
15 Scalable infrastructure for marketing U.S OTC brands Contract Manufacturers Sales Force Retailers/ Wholesalers Sales and marketing/brand Management Logistics Note: Largest retailers and wholesalers only, not an all inclusive list.
16 Closed Balmex acquisition April 24, 2015 Acquired from Chattem (Sanofi) for $3.9 million (MSEK 33.3) Sales trending above $4 million annually Deal financed with existing funds Strong heritage in baby diaper rash with broad distribution in major chains: 15 15
17 Distributor Sales well positioned for further growth Sales in >40 markets Growth in Europe (+7%) - Emtrix rights in six EU markets taken back Asian launches progresses well and rapid growth of sales - 6 markets launched - Ongoing preparations in other Large growth potential Note: Four largest distributors only, not an all inclusive list.bv 16 16
18 Launches in Asia a key growth driver Malaysia Launch Q4 2014, already market leader Hong Kong Excellent start of sales and reorders Singapore Launch started, to be ramped up China Regional launch started in May 2015 Indonesia Launch and TV started Aug 2015 Philippines Launch started Nov Other markets Launch preparations ongoing 17
19 Innovation Engine
20 Pipeline assets - Building on Topical drug delivery know how Pipeline asset Indication Status MOB-015 Onychomycosis Ph III preparation BUPI Oral Mucositis and oral pain Ph III preparation Peak sales potential, m$ USP Topical terbinafine with fast visible improvement and superior cure rates Lozenge formulation with effective pain relief for 2-3 hrs(vs 0,5 hrs for competition) 19 19
21 MOB-015 USPs and Strategy USPs Targets a superior profile, in mild to moderate onychomycosis based on phase II data and experience from the OTC product (>600 patients in clinical trials and >10 million units sold to date): 1 Superior cure rates Mycological and Clinical 2 Shorter treatment time potentially 6 months 3 First visible improvement within 2-4 weeks Strategy Prepare Phase III to start in 2016 Objective to maintain control of asset in key territories through phase III 20 20
22 BUPI targets to provide additional and prolonged pain relief Product & Indication BUPI (bupivacaine lozenge) for oral pain relief (mouth and throat) 1 st indication: Oral Mucositis in cancer patients. Large unmet need Other indications: Burning Mouth Syndrome, Sjögren s syndrome, Upper gastrointestinal endoscopy. Long-term also OTC potential. Value and Next steps Peak Sales potential $50-100m, whereof the OM indication is $20-25m Positive topline Phase II data 21 21
23 Innovation Engine 4 ACQUISITIONS LAST 40 MONTHS 4 PATENTS APPROVED 2015 Organic growth Current products growing, adding new markets Line extensions adding incremental growth - Focus on strategic brands 5 patent families enable additional products - MOB-015, K-Nail+ patents granted Acquisitions/inlicensing Brands - Focus on US OTC market Pipeline assets enabling new products Completed Acquisitions Alterna LLC, Nov 2012, $26m (2.3x Sales) Bayer brands, Dec 2013, $4.8m (1.6x Sales) Bupizenge, April 2014, dev. project,$1m Balmex, April 2015, $3.9m (<1x Net Sales) 22 22
24 Focus next 12 months PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Intends to make significant investments in Strengthening strategic brands in U.S. - Broadening international distribution, - Acquiring additional products/assets - Initiating phase III studies for MOB-015 U.S: Execution of Kerasal brand strategy Asia key growth driver, additional launches Long-term target Create shareholder value through profitable growth targeting a long-term EBITDA margin of at least 25% 23 23
25 Why invest in Moberg Pharma Commercial niche strategy enables a growing and profitable base business Pipeline with large potential and at reasonable risk - Proven molecules limit development risk, cost and TTM Acquisition strategy with substantial value potential - 4 acquisitions in last 40 months - Team, systems and infrastructure in place to enable scale-up - Capacity to finance deals Strong Team with track record 24 24
26 Q&A 25 25
Moberg Pharma AB CREATING A FOOTPRINT IN UNDERSERVED NICHES. Presentation at Redeye Investor Forum September 6, 2016 Anna Ljung, CFO
Moberg Pharma AB CREATING A FOOTPRINT IN UNDERSERVED NICHES Presentation at Redeye Investor Forum September 6, 2016 Anna Ljung, CFO 0 Disclaimer Statements included herein that are not historical facts
More informationMoberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES
Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation, Nordic Life Science Days September 9 th 2015 Anna Ljung, CFO Disclaimer Statements included herein that are not
More informationCREATING A FOOTPRINT IN UNDERSERVED NICHES
Moberg Pharma AB CREATING A FOOTPRINT IN UNDERSERVED NICHES Presentation at Swedbank September 8, 2016 Peter Wolpert, CEO/Founder and Anna Ljung, CFO 0 Disclaimer Statements included herein that are not
More informationMOBERG PHARMA AB (PUBL) Interim Report Jan-Mar 2015 Combining Commercial and Innovation Excellence to Develop Unique Products for Underserved Niches
MOBERG PHARMA AB (PUBL) Interim Report Jan-Mar 2015 Combining Commercial and Innovation Excellence to Develop Unique Products for Underserved Niches Press conference, May 11, 2015 at 10:30 a.m. (CET) Dial-in
More informationMOBERG PHARMA AB (PUBL) Year-End Report 2014 Combining Commercial and Innovation Excellence to Develop Unique Products for Underserved Niches
MOBERG PHARMA AB (PUBL) Year-End Report 2014 Combining Commercial and Innovation Excellence to Develop Unique Products for Underserved Niches Stockholm Corporate Finance Life Science/Healthcare day, March
More informationMoberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES
Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation Swedbank Health Care Seminar, 4 December 2015 Peter Wolpert, CEO & Founder 0 Disclaimer Statements included herein
More informationMoberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES
Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation Meetings at JPM, San Francisco, 11 January 2015 Peter Wolpert, CEO & Founder 0 Disclaimer Statements included herein
More informationInterim report January September 2016
Interim report January September 2016 Conference call, November 8, 2016 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 426 95, US: +1 646 502 51 20 Peter Wolpert, CEO & Founder Anna Ljung, CFO Disclaimer
More informationCreating a footprint in underserved niches. Stockholm Corporate Finance Life Science Seminar March 21 th, 2017 Peter Wolpert, CEO & Founder
Creating a footprint in underserved niches Stockholm Corporate Finance Life Science Seminar March 21 th, 2017 Peter Wolpert, CEO & Founder Disclaimer The purpose of this presentation (the "Presentation")
More informationYear-end report January December 2016
Year-end report January December 2016 Presentation at Pareto Securities, February 14 th, 2017 Peter Wolpert, CEO & Founder Mark Beveridge, Business Controller Disclaimer The purpose of this presentation
More informationMoberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES. Presentation at SEB - Bolagsdagen September 18, 2015 Peter Wolpert, CEO & Founder
Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Presentation at SEB - Bolagsdagen September 18, 2015 Peter Wolpert, CEO & Founder Disclaimer Statements included herein that are not historical
More informationMoberg Pharma AB (Publ) Interim Report January June 2015
Moberg Pharma AB (Publ) Interim Report January June 2015 CONTINUED SEQUENTIAL GROWTH Strong performance across the board, including launches in Asia as a key driver, resulted in a second quarter with excellent
More informationInterim report January-June 2013 A DIFFERENT KIND OF PHARMA COMPANY
Interim report January-June 2013 A DIFFERENT KIND OF PHARMA COMPANY Telephone conference, August 6, 2013 at 10:30 a.m. (CET) Dial-in number: +46 8-506 26 900, enter code: 409017 Peter Wolpert, CEO and
More informationMoberg Pharma AB (Publ) INTERIM REPORT JANUARY SEPTEMBER 2015
Moberg Pharma AB (Publ) CONTINUED GROWTH AND DOUBLING OF PROFIT Strong performance, with our distributor sales in Asia as a key driver, resulted in a third quarter with topline growth and continued improvement
More informationCREATING A FOOTPRINT IN UNDERSERVED NICHES. Annual Report 2015
CREATING A FOOTPRINT IN UNDERSERVED NICHES Annual Report 2015 moberg pharma PHARMA IN BRIEF SHARE PRICE PERFORMANCE SINCE LISTING SEK 80 No. 1 200 WHY WE ARE PERFORMING Moberg Pharma s corporate strategy
More informationInterim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY
Interim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY Press conference, May 21, 2013 at 10:00 a.m. (CET) Dial-in number: +46 8-50626900, enter code: 409017 Peter Wolpert, CEO and founder
More informationInterim report January March Moberg Pharma AB (Publ) Q2 Q3 Q4 MOBERG PHARMA AB (PUBL) YEAR-END REPORT 2016
Interim report January March 2017 Moberg Pharma AB (Publ) Q1 Q2 Q3 Q4 MOBERG PHARMA AB (PUBL) 556697-7426 YEAR-END REPORT 2016 1 CONTINUED STRONG GROWTH IN EBITDA The year got off to an intense start with
More informationMoberg Pharma AB (Publ) Year-end Report 2014
Moberg Pharma AB (Publ) Year-end Report 2014 SUCCESSFUL FOURTH QUARTER AND THE FIRST PROFITABLE FULL YEAR After a strong fourth quarter with 38% growth in product sales, we achieved two major milestones
More informationInterim report January June Moberg Pharma AB (Publ) Q3 Q4 MOBERG PHARMA AB (PUBL) YEAR-END REPORT 2016
Interim report January June 2017 Moberg Pharma AB (Publ) Q1 Q2 Q3 Q4 MOBERG PHARMA AB (PUBL) 556697-7426 YEAR-END REPORT 2016 1 OUR THREE LARGEST BRANDS ARE DEVELOPING WELL "Kerasal Nail reached a market
More informationMoberg Pharma AB (Publ) Interim Report January September
Moberg Pharma AB (Publ) Interim Report January September SUCCESSFUL THIRD QUARTER We made excellent progress in the third quarter, growing at 35% with improved profitability and reporting strong phase
More informationPROFITABLE AND GROWING
PROFITABLE AND GROWING Annual Report 2014 moberg pharma CONTENTS Moberg Pharma in brief 3 CEO Commentary 6 Market dynamics and strategy 8 Brands and products 11 Innovation engine 13 Organization and employees
More informationInterim report January September Moberg Pharma AB (Publ) Q1 Q2 MOBERG PHARMA AB (PUBL) BOKSLUTSKOMMUNIKÈ 2016
Interim report January September 2017 Moberg Pharma AB (Publ) Q1 Q2 Q3 Q4 MOBERG PHARMA AB (PUBL) 556697-7426 BOKSLUTSKOMMUNIKÈ 2016 1 SUCCESS FOR NEW SKIN Strong development for our three largest brands
More informationYear-end report Moberg Pharma AB (publ) Q1 Q2 Q3 MOBERG PHARMA AB (PUBL) BOKSLUTSKOMMUNIKÉ 2016
Year-end report 2018 Moberg Pharma AB (publ) Q1 Q2 Q3 Q4 MOBERG PHARMA AB (PUBL) 556697-7426 BOKSLUTSKOMMUNIKÉ 2016 1 MAJOR TRANSFORMATION OF THE COMPANY AFTER A STRONG YEAR As we conclude 2018, we re
More informationMoberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY. Corporate Presentation August 29, 2013 Peter Wolpert, CEO and Founder
Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY Corporate Presentation August 29, 2013 Peter Wolpert, CEO and Founder 0 Disclaimer Statements included herein that are not historical facts are forward-looking
More informationCreating a footprint in underserved niches. Swedbank Healthcare Seminar, December 1, 2016 Peter Wolpert, CEO & Founder
Creating a footprint in underserved niches Swedbank Healthcare Seminar, December 1, 2016 Peter Wolpert, CEO & Founder Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview
More informationCONTINUED GROWTH AND INCREASED FINANCIAL STRENGTH PREPARING FOR PORTFOLIO EXPANSION
Moberg Pharma AB (Publ) Interim Report January June 2013 CONTINUED GROWTH AND INCREASED FINANCIAL STRENGTH PREPARING FOR PORTFOLIO EXPANSION Strong demand for our products, a larger geographical reach
More informationCreating a footprint in underserved niches. Carnegie Helthcare Day, New York, December 5, 2017 Peter Wolpert, CEO & Founder Anna Ljung, CFO
Creating a footprint in underserved niches Carnegie Helthcare Day, New York, December 5, 2017 Peter Wolpert, CEO & Founder Anna Ljung, CFO Disclaimer Statements included herein that are not historical
More information53% Growth in product sales in the third quarter compared with the year-earlier period. 77% Gross margin, third quarter
Moberg Pharma AB (Publ) Interim Report January September KERASAL NAIL IS MARKET LEADER IN U.S. Continued strong growth in the U.S., the launch of Kerasal Neurocream in the U.S. and the partnership with
More informationCONTINUED STRONG GROWTH - MOBERG DERMA BECOMES MOBERG PHARMA
Moberg Pharma AB (publ) Interim report January March CONTINUED STRONG GROWTH - MOBERG DERMA BECOMES MOBERG PHARMA Sales rose 129 percent compared with the first quarter of 2012. The sharp increase resulted
More informationMoberg Derma AB (Publ) Year-end report 2012
Moberg Derma AB (Publ) Year-end report 2012 DOUBLED REVENUE, PROFITABLE AND ESTABLISHMENT IN THE U.S. The key factor that enabled us to double our revenue in 2012 and achieve profitability one year ahead
More informationMoberg Derma AB (Publ) Interim report January - March
Moberg Derma AB (Publ) Interim report January - March CONTINUED STRONG GROWTH AND PROFITABILITY Launches have either already commenced or will start shortly in many European markets. The strong growth
More informationMoberg Derma AB (Publ) Interim report January-June
Moberg Derma AB (Publ) Interim report January-June EUROPEAN LAUNCHES DRIVES CONTINUED STRONG GROWTH Launches in eight countries in Europe, including France, Germany and Italy were successfully rolled out
More informationCarnegie Healthcare Conference. March 12, 2014
Carnegie Healthcare Conference March 12, 2014 1 Meda - overview A leading specialty pharma company: 48th largest pharmaceutical company 15th largest specialty pharma company Own sales organization in close
More informationCatalent, Inc. Jefferies Global Healthcare Conference. June 9, DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.
Catalent, Inc. Jefferies Global Healthcare Conference June 9, 2016 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied. Disclaimer Statement Forward-Looking Statements This
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationAccelerating our IPT strategy
Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationCorporate Presentation
Corporate Presentation The presentation herein may contain forward looking statements by the management of Best World International Ltd (BWI) that pertain to expectations for financial performance of future
More informationA DIFFERENT PHARMACEUTICAL COMPANY
annual report 2012 moberg derma CONTENTS Derma in brief 3 CEO commentary 5 Market and sales 7 Products launched 13 New products and business opportunities 18 Organization and employees 24 Patents and brands
More informationNEW NORDIC HEALTHBRANDS AB (PUBL) NINE MONTH REPORT JANUARY - SEPTEMBER 2018
NEW NORDIC HEALTHBRANDS AB (PUBL) NINE MONTH REPORT JANUARY - SEPTEMBER 218 218 217 Net sales, ksek 296 77 258 97 112 697 88 315 Change in SEK, % 14.7% 9.7% 27.6% 4.2% Change in local currencies, % 1.%
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationSinclair IS Pharma plc Investor Presentation. April 2012
Sinclair IS Pharma plc Investor Presentation April 2012 Disclaimer The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been
More informationFinancial Results for the Fiscal Year Ended December, Lion Corporation Itsuo Hama Representative Director and President, Executive Officer
February 10, 2017 Financial Results for the Fiscal Year Ended December, 2016 Lion Corporation Itsuo Hama Representative Director and President, Executive Officer Contents Financial Results for 2016 Financial
More informationPBH at a Glance. Business Overview. Business. Overview
NYSE: PBH Welcome Statements in this presentation which are not historical facts, including, without limitation, reporting financial guidance for Fiscal 2008, are forward-looking statements within the
More informationC-RAD AB - CONSOLIDATED YEAR-END REPORT
C-RAD AB - CONSOLIDATED YEAR-END REPORT JANUARY DECEMBER 2017 PRESS RELEASE JANUARY 31, 2018 POSITIVE RESULT FOR THE FOURTH QUARTER 2017 FOURTH QUARTER 2017 Order intake: 47.5 (41.9) MSEK, +13%. Revenues:
More informationTELECONFERENCE Q FINANCIAL RESULTS
TELECONFERENCE FINANCIAL RESULTS 10:00 CET, 13 May 2014 1 AGENDA AGENDA Business highlights: Key developments in Market development and sales-out Performance of newly launched products Guidance 2014 Financial
More informationOn the Road to Sustained Growth FY2015 Q2
On the Road to Sustained Growth FY2015 Q2 October 30, 2015 Christophe Weber President & Chief Executive Officer Important Notice Forward-Looking Statements This presentation contains forward-looking statements
More informationQ3 report 2018 Press and analyst presentation. 25 October, 2018 Per Strömberg, CEO Sven Lindskog, CFO
Q3 report 2018 Press and analyst presentation 25 October, 2018 Per Strömberg, CEO Sven Lindskog, CFO In brief Improved EBIT Logistic costs weighing down profits High activity level continues 2 Improved
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationFor personal use only
Mayne Pharma Group Limited FY16 Results Presentation 26 August 2016 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO 1 Disclaimer The information provided is general in nature and is in
More informationBioInvent issues private placement to US-based healthcare investor Omega Funds in parallel to offering a fully guaranteed rights issue
Press release 16 February 2016 This press release may not be published or distributed, directly or indirectly, in or into the United States, Canada, Hong Kong, Japan, South Africa, Australia or any other
More informationTELECONFERENCE Q FINANCIAL RESULTS
TELECONFERENCE Q3 2013 FINANCIAL RESULTS 10:00 CET, 12 November 2013 1 AUGUST 2013 INVESTOR PRESENTATION AGENDA AGENDA Business highlights: Key developments in Q3 2013 Market development and sales-out
More informationHeading back to profitable growth
Commerzbank German Investment Seminar 2010 New York January 12, 2010 Dr. Kurt Bock, CFO Heading back to profitable growth 1 Forward-looking statements This presentation includes forward-looking statements
More informationYear-end report 2017 Press and analyst presentation
Year-end report 2017 Press and analyst presentation 8 February, 2018 Per Strömberg, CEO Sven Lindskog, CFO In brief Good sales momentum in Sweden Robust underlying EBIT and cash flow Strong online growth
More informationFinancial Results Analysis Quarter & 9 Months Ended December 31, 2011
Financial Results Analysis Quarter & 9 Months Ended December 31, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More informationInterim Report, First Quarter 2014
Interim Report, First Quarter 2014 CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE FIRST QUARTER 2014 FIRST AND POST QUARTER HIGHLIGHTS Continued progress on the start-up of NormoCort Phase 3 trial While
More informationAnders Lidbeck, President & CEO. February 11, 2016
Anders Lidbeck, President & CEO February 11, 2016 Agenda Enea Intro Enea Financials Q415 & FY15 Way Forward & Outlook A Catalyst for the Connected Society HEAD QUARTER KISTA, SWEDEN REVENUE 481.5 MSEK
More informationCatalent, Inc. 34 th Annual J.P. Morgan Healthcare Conference. John Chiminski President & CEO January 11, 2016
Catalent, Inc. 34 th Annual J.P. Morgan Healthcare Conference John Chiminski President & CEO January 11, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical
More informationMakes it easier to be professional
Makes it easier to be professional Handelsbanken Nordic Mid/small Cap Seminar June 8, 2017 President and CEO Johan Nilsson 2 2 Introduction One-Stop-Shop multi channel offering for professionals Branches
More informationFinancial Results Analysis Quarter & Half Year Ended September 30, 2011
Financial Results Analysis Quarter & Half Year Ended September 30, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationInvestor Presentation. March 2016
Investor Presentation March 2016 Safe Harbor Statement This presentation includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation
More information1Q11 & FY10 Financial Results May 11, 2011
1Q11 & FY10 Financial Results May 11, 2011 1 Disclaimer These presentations and discussions contain certain forward looking statements with respect to the results of operation, financial condition and
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationVOLVO CAR GROUP results presentation Third quarter and first nine months 2018
VOLVO CAR GROUP results presentation Third quarter and first nine months 2018 Nils Mösko, vice president & Head of investor relations Patrik Tolf, Deputy CFO & head of Group Finance DISCLAIMER By accepting
More informationPerrigo Fiscal Fourth Quarter Conference Call August 18, 2009
Perrigo Fiscal Fourth Quarter Conference Call August 18, 2009 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the
More informationFull Year 2017 Earnings. Press Conference February 22, 2018
Full Year 2017 Earnings Press Conference February 22, 2018 IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS Certain statements contained herein may be forward-looking
More informationPERFORMANCE AMID HEADWINDS
Stefan Oschmann, CEO Marcus Kuhnert, CFO PERFORMANCE AMID HEADWINDS March 8, 2018 We have met all financial targets for 2017 15.3 bn 15.7 bn 4,400 m 4,600 m 6.15 6.50 15,327 m 4,414 m 6.16 Totals may not
More informationQ Financial Results (unaudited)
Q4 2016 Financial Results (unaudited) Supplemental information to earnings release February 7, 2017 Forward-looking statements Any statements in this presentation about future expectations, plans and prospects
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationQ3 report 2017 Press and analyst presentation
Q3 report 2017 Press and analyst presentation 10 November, 2017 Per Strömberg, CEO Sven Lindskog, CFO In brief Stable EBIT development Strong online growth Intense focus on new ventures 2 Stable earnings
More informationJUBILANT LIFE SCIENCES Q4/FY2017 RESULTS
PRESS RELEASE Noida, Tuesday, May 23, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4/FY2017 RESULTS JUBILANT REPORTS
More informationACETO Corporation. June 8, 2016
NASDAQ:ACET ACETO Corporation Jefferies Healthcare Conference June 8, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by
More informationTELECONFERENCE Q FINANCIAL RESULTS. 10:00 CET, 10 November 2015
TELECONFERENCE FINANCIAL RESULTS 10:00 CET, 10 November 2015 1 AGENDA AGENDA Business highlights: Key developments in Market development and sales-out Guidance 2015 Financial review for Recap and Q&A 2
More informationNew Nordic Healthbrands AB (publ) Three month report January - March 2017
New Nordic Healthbrands AB (publ) Three month report January - March 2017 Q1 2017 Q1 2016 Full Year 2016 Net sales, ksek 80 908 74 576 306 842 Change in local currencies, % 6.0 5.1 3.2 Gross profit, ksek
More informationTELECONFERENCE FY 2014 FINANCIAL RESULTS
TELECONFERENCE FY 2014 FINANCIAL RESULTS 10:00 CET, 17 February 2015 1 DISCLAIMER Certain statements in this presentation constitute forward-looking statements. Forward-looking statements are statements
More informationHELLA Investor Update 9M FY 2017/18
HELLA Investor Update 2017/18 Conference Call on March 22, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationTELECONFERENCE Q FINANCIAL RESULTS 10:00 CET, 10 MAY 2016
TELECONFERENCE 2016 FINANCIAL RESULTS 10:00 CET, 10 MAY 2016 AGENDA FINANCIAL HIGHLIGHTS 2016 FINANCIAL EXPECTATIONS 2016 FINANCIAL REVIEW 2016 SUMMARY 2 DISCLAIMER Certain statements in this presentation
More informationFull Year Results th February 2012
Full Year Results 2011 7 th February 2012 Sir Andrew Witty Chief Executive Officer Simon Dingemans Chief Financial Officer Delivering our strategy Grow a diversified global business Deliver more products
More informationINTERIM RESULTS PRESENTATION Strong start to the year, with a strong order book for the second half of September 2017
INTERIM RESULTS PRESENTATION Strong start to the year, with a strong order book for the second half of 2017 11 September 2017 AGENDA Introduction and highlights John Hornby Financial review David Main
More informationProfitable Growth : Why Acquisitions Matter at Least in Some Industries
Profitable Growth : Why Acquisitions Matter at Least in Some Industries SAMBA plus SAM-Talk: Zurich, 29 th of April 2014 By: Dr. Thomas W. Schrepfer, MBA, LL.M. 1 Agenda 1 Profitable Growth 2 3 4 Organic
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationUnless otherwise stated in this report, all data refers to the Group. Numbers in parentheses relate to the corresponding period in 2016.
Summary Unless otherwise stated in this report, all data refers to the Group. Numbers in parentheses relate to the corresponding period in 2016. Financial overview Q3 2017 Total net revenues SEK 166.2
More informationSivantos Investor Presentation H1 FY2017
Sivantos Investor Presentation H1 FY2017 Ignacio Martinez, CEO Dr Wolfgang Ollig, CFO 06 June 2017 Sivantos 2015 All rights reserved/restricted. Disclaimer This document contains statements related to
More informationHELLA Investor Update H1 FY 2017/18
HELLA Investor Update 2017/18 Conference Call on January 11, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.
More informationQ2 Results 2010 Presentation to Investors & Analysts. 21 st July 2010
1 Q2 Results 2010 Presentation to Investors & Analysts 21 st July 2010 Julian Heslop Chief Financial Officer 2 Financial summary Turnover Operating profit* EPS Free cash flow Q2 10 H1 10 m m 7,025 14,382
More informationWebcast Year end results February 19, 2014
Webcast Year end results 2013 February 19, 2014 1 Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of
More informationYear End Report 2017 February 13, Magnus Welander, CEO Lennart Mauritzson, CFO
Year End Report 2017 Magnus Welander, CEO Lennart Mauritzson, CFO 2017/Q4 Continued good performance in smallest quarter of the year Net sales of SEK 1,006m (983) +2.3% (+6.5% excluding currency effects)
More informationYear-end Report Jan Johansson, President and CEO
Jan Johansson, President and CEO Summary Full year 2010 EBIT increased 4%* Higher volumes in all businesses Higher prices in Packaging and Tissue SEK 1bn in cost savings Significant profit improvement
More informationAFT PHARMACEUTICALS Annual Meeting 3 August 2018
AFT PHARMACEUTICALS 3 August 2018 IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited ( AFT ), to provide a general overview of AFT. It is not prepared for any other purpose
More informationTELECONFERENCE PRESENTATION Q1 2012
TELECONFERENCE PRESENTATION Q1 2012 8 May 2012 1 AGENDA AGENDA Important events in Q1 2012 Stock balancing campaign Realigned price architecture and product range Financial highlights Q&A 2 DISCLAIMER
More informationHELLA Investor Update FY 2017/18
HELLA Investor Update FY 2017/18 Conference Call on August 10, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.
More informationTELECONFERENCE PRESENTATION Q2 2012
TELECONFERENCE PRESENTATION Q2 2012 7 August 2012 1 AGENDA AGENDA Important events in Q2 2012 Financial highlights Q&A 2 DISCLAIMER Certain statements in this presentation constitute forward-looking statements.
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More information